On April 12, 2022, Hinova Pharmaceuticals Inc. ( “Hinova Pharma” or the “Company”, stock code: 688302) was successfully listed on the Shanghai Stock Exchange STAR Market ( the “Project”). JunHe acted as the counsel to the issuer. Hinova Pharma publicly issued 24,760,000 new shares at RMB 42.92 per share, accounting for 25.01% of the total share capital after this issue and raising a total amount of RMB 1,062,699,200.
Established in February 2013, Hinova Pharma is an international clinical-stage pharmaceutical company. It is engaged in the development of best-in-class and first-in-class deuterated and PROTAC (PROteolysis Targeting Chimera) drugs. Since its establishment, the Company has gradually built and improved four core R&D platforms: a deuteration platform, a PROTAC (PROteolysis Targeting Chimera) platform, a novel target discovery and validation platform, and a lead compound optimization screening platform. The Company focuses on developing new therapeutic medicines for cancers and metabolic syndromes through PROTAC and deuteration technology and is committed to the discovery and development of innovative drugs with global appeal.
As the counsel to the issuer, JunHe participated throughout the IPO of the Company on the STAR Market. This included assisting the Company in dismantling its overseas red-chip structure, the pre-IPO private financing, shareholding reform matters, developing the ESOP, patent FTO investigation, and other material legal matters. JunHe was unanimously recognized by the Company and the other intermediaries for its efficient and prudent delivery of professional legal services.
This Project was led by Mr. TAO, Xudong and Mr. SHI, Tiejun, and the FTO investigation was led by Dr. WANG, Zhaohui (Zoe) and WU, Yu (Sophia).